No abstract

Dysken, M.W., S. Anton-Johnson, L. Klein, M. Kuskowski, L.J. Schut, S.H. Miles, G.J. Maletta, and R. DeJong: CI-911: A placebo-controlled study in patients with primary degenerative dementia. Drug Dev. Res. 12:267-270, 1988.Twenty patients with primary degenerative dementia participated in a 6-week, doseranging, double-blind, placebo-controlled study of CI-911, a cognition activator that enhances performance in animal models of impaired cognition. CI-911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self-care.Address reprint requests to Maurice W. Dysken, M.D., GRECC Program (llG), Minneapolis VA Medical Center, 54th Street and 48th Ave. S . , Minneapolis, MN 55417.